Out-of-pocket costs for Medicare beneficiaries are rising. It's time for policymakers to act.
Why do some patients so much more?
What began as a safeguard against unnecessary drug spending has become a significant barrier to patient access.
Innovation comes at a price, one that health insurers may hesitate to pay.
Macroeconomic pressures have hit the R&D returns of life sciences firms.
Learn more about the insurance practice called step therapy.